Metastatic Prostate Cancer

Alliance for Cancer Gene Therapy awarded a $500,000 grant to researchers at University of Pennsylvania’s Abramson Cancer Center to develop new chimeric antigen receptor T-cell therapies for advanced metastatic prostate cancer.

The FDA granted priority review to rucaparib for treatment of advanced prostate cancer, according to the agent’s manufacturer.

BARCELONA, Spain — Cabazitaxel significantly improved outcomes compared with androgen receptor-targeted therapies for certain men with previously treated metastatic castration-resistant prostate cancer, according to results of the randomized CARD study presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — The addition of upfront docetaxel chemotherapy to androgen deprivation therapy conferred durable, clinically significant benefit for men with low- and high-burden metastatic prostate cancer, according to results of the randomized phase 3 STAMPEDE trial presented at European Society for Medical Oncology Congress.

The FDA expanded the approval of apalutamide to include treatment of men with metastatic castration-sensitive prostate cancer.

The FDA has granted priority review to enzalutamide for the treatment of men with metastatic hormone-sensitive prostate cancer, according to a press release from the drug’s manufacturer.